Table 1.
Characteristics of study population (n = 243)
| Characteristics | n (max, min) | % |
|---|---|---|
| Age (years)* | 49 (10, 87) | |
| Male | 157 | 64.6 |
| Fibrosis stage† (n = 66) | ||
| F0 (< 5.1 kPa) | 3 | 4.5 |
| F1 (≥ 5.1 and < 7.2 kPa) | 4 | 6.1 |
| F2 (≥ 7.2 and < 9.6 kPa) | 19 | 28.8 |
| F3 (≥ 9.6 and < 14.1 kPa) | 20 | 30.3 |
| F4 (≥ 14.1 kPa) | 20 | 30.3 |
| History of HCV treatment (n = 48)‡ | ||
| IFN or PegIFN | 44 | 91.7 |
| DAA§ | 7 | 14.6 |
| Both IFN/PegIFN and DAA | 3 | 6.3 |
| HCV genotypes (n = 172)‖ | ||
| 1 | 108 | 62.8 |
| 1a | 57 | 33.1 |
| 1b | 40 | 23.3 |
| Subtype unknown | 11 | 6.4 |
| 2 | 20 | 11.6 |
| 2a/c | 14 | 8.1 |
| Subtype unknown | 6 | 3.5 |
| 3 | 26 | 15.1 |
| 3a | 15 | 8.7 |
| 3k | 11 | 6.4 |
| 4 | 17 | 9.9 |
| 4h | 6 | 3.5 |
| Subtype unknown | 11 | 6.4 |
| 6 | 1 | 0.6 |
| 6c | 1 | 0.6 |
| Indeterminate | 8 | 4.7 |
*
Median (minimum, maximum).
†
By transient elastography (TE) using FibroScan®, cirrhosis was defined as having a TE value of 14.1 kPa or above (fibrosis stage 4) [31].
‡
With previous HCV treatment.
§
Either daclatasvir/sofosbuvir or sofosbuvir/ledipasvir with or without ribavirin.
‖
Genotypes among 180 patients with quantifiable viral load by Roche HCV.